Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Mass Spectrometry

• Publication date

  2008-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jms.1369PMID 18286663
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

  2006cited by this paper
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006cited by this paper
• The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?

  2006cited by this paper
• METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

  2006cited by this paper
• Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.

  2006cited by this paper
• Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers.

  2006cited by this paper
• METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

  2005cited by this paper
• Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia

  2005cited by this paper
• Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer

  2005cited by this paper
• Severe Hepatic Injury Caused by Imatinib Mesylate Administered for the Treatment of Chronic Myeloid Leukemia and the Efficacy of Prednisolone for its Management

  2005cited by this paper
• Effects of Imatinib on Normal Hematopoiesis and Immune Activation

  2005cited by this paper
• Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance

  2005cited by this paper
• Cytochrome P450-dependent metabolism of gefitinib

  2005cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

  2004cited by this paper
• Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir.

  2004cited by this paper
• Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

  2004cited by this paper
• Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

  2004cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004cited by this paper
• Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

  2004cited by this paper
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• Protein precipitation for the analysis of a drug cocktail in plasma by LC-ESI-MS.

  2004cited by this paper
• Cytochromes P450 in the bioactivation of chemicals.

  2004cited by this paper
• High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

  2004cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Metabolite identification in drug discovery.

  2003cited by this paper
• Lessons learned from the irinotecan metabolic pathway.

  2003cited by this paper
• Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.

  2003cited by this paper
• Tamoxifen: a most unlikely pioneering medicine

  2003cited by this paper
• Imatinib treatment: specific issues related to safety, fertility, and pregnancy.

  2003cited by this paper
• Generic solid phase extraction-liquid chromatography-tandem mass spectrometry method for fast determination of drugs in biological fluids.

  2003cited by this paper
• Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.

  2003cited by this paper
• Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.

  2003cited by this paper
• Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.

  2003cited by this paper
• Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

  2002cited by this paper
• Determination of drug concentrations in plasma by a highly automated, generic and flexible protein precipitation and liquid chromatography/tandem mass spectrometry method applicable to the drug discovery environment.

  2002cited by this paper
• Tumour cytochrome P450 and drug activation.

  2002cited by this paper
• Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.

  2001cited by this paper
• Bioanalytical Method Validation—A Revisit with a Decade of Progress

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates.

  1999cited by this paper

• Imatinib Detection by Memristive Biosensors for Therapeutic Drug Monitoring

  2025cites this paper
• Drug Interaction of Dasatinib with Thymoquinone: A Pharmacokinetic Study in Rats

  2025cites this paper
• Pharmacokinetics of Dasatinib in Rats: a Potential Food–Drug Interaction with Naringenin

  2024cites this paper
• Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism

  2023cites this paper
• Herb-drug interaction: Effect of sinapic acid on the pharmacokinetics of dasatinib in rats

  2023cites this paper
• A Study of the Identification, Fragmentation Mode and Metabolic Pathways of Imatinib in Rats Using UHPLC-Q-TOF-MS/MS

  2021cites this paper
• Towards point of care systems for the therapeutic drug monitoring of imatinib

  2020cites this paper
• Metabolite Profiling in Anticancer Drug Development: A Systematic Review

  2020cites this paper
• DDDT_A_221518 1401..1444

  2020cites this paper
• VISIBLE SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND VALIDATION OF IMATINIB IN BULK AND FORMULATION

  2020cites this paper
• Thermosensitive molecularly imprinted poly(1-Vinyl-2-pyrrolidone/ Methyl methacrylate /N-vinylcaprolactam) for selective extraction of imatinib mesylate in human biological fluid.

  2019cites this paper
• Ultra-performance LC-MS/MS study of the pharmacokinetic interaction of imatinib with selected vitamin preparations in rats.

  2018cites this paper
• Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

  2018cites this paper
• Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS

  2018cites this paper
• Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.

  2017influential citation
• Novel sulphur‐containing imatinib metabolites found by untargeted LC‐HRMS analysis

  2017cites this paper
• HPLC-UV ASSAY OF IMATINIB IN HUMAN PLASMA OPTIMIZED FOR BIOEQUIVALENCE STUDIES.

  2016cites this paper
• A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

  2016cites this paper
• Simultaneous quantification of imatinib and CGP74588 in human plasma by liquid chromatography-time of flight mass spectrometry (LC-TOF-MS)

  2016cites this paper
• Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods.

  2016cites this paper
• The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process.

  2015cites this paper
• Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry.

  2015cites this paper
• Detailed study of imatinib metabolization using high-resolution mass spectrometry.

  2015cites this paper
• Spectrophotometric Determination of Imatinib Mesylate using Charge Transfer Complexs in Pure Form and Pharmaceutical Formulation

  2014cites this paper
• Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology

  2014cites this paper
• LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.

  2014cites this paper
• Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance

  2014cites this paper
• Development and validation of a non-aqueous capillary electrophoresis method for the determination of imatinib, codeine and morphine in human urine

  2014cites this paper
• Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

  2014cites this paper
• CYP 3 A activity influences imatinib response in patients with chronic myeloid leukemia : a pilot study on in vivo CYP 3 A activity

  2013cites this paper
• and nilotinib Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib,

  2013cites this paper
• Identification of urinary metabolites of imperatorin with a single run on an LC/Triple TOF system based on multiple mass defect filter data acquisition and multiple data mining techniques

  2013cites this paper
• Rapid Determination of Imatinib in Human Plasma by Liquid Chromatography- Tandem Mass Spectrometry: Application to a Pharmacokinetic Study

  2013cites this paper
• Development and validation of an high performance liquid chromatography-tandem mass spectrometry method for the determination of imatinib in rat tissues.

  2013cites this paper
• Influence of CYP3A enzymes and ABC transporters on the activity of tyrosine kinase inhibitors in chronic myeloid leukemia

  2013cites this paper
• Therapeutic drug monitoring and LC-MS/MS.

  2012cites this paper
• Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

  2012cites this paper
• Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

  2012cites this paper
• PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.

  2012cites this paper
• Potentiometric Determination of Imatinib under Batch and Flow Injection Analysis Conditions

  2012cites this paper
• Metabolite identification by liquid chromatography-mass spectrometry

  2011cites this paper
• Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

  2011cites this paper
• Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection.

  2011cites this paper
• Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

  2011cites this paper
• Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.

  2011cites this paper
• A method for quantitative analysis of an anticancer drug in human plasma with CE‐ESI‐TOF‐MS

  2011cites this paper
• A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.

  2011cites this paper
• Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.

  2010cites this paper
• Hydride transfer reactions via ion-neutral complex: fragmentation of protonated N-benzylpiperidines and protonated N-benzylpiperazines in mass spectrometry.

  2010cites this paper
• Therapeutic drug monitoring in cancer chemotherapy.

  2010cites this paper
• Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.

  2010cites this paper
• Cardiovascular drug interactions with tyrosine kinase inhibitors

  2010cites this paper
• Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

  2009cites this paper
• Implications of the dominant role of transporters in drug uptake by cells.

  2009cites this paper
• Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.

  2009cites this paper
• Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.

  2009cites this paper
• Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma

  2009cites this paper
• Therapeutic drug monitoring in oncology: does it have a future?

  2009cites this paper
• Characterization of imatinib metabolites in rat and human liver microsomes: differentiation of hydroxylation from N-oxidation by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.

  2009cites this paper
• IMATINIB QUANTIFICATION IN RAT PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH ULTRA VIOLET DETECTION-AN APPLICATION TO PRECLINICAL PHARMACOKINETIC STUDY

  2008cites this paper
• Chronic myeloid leukemia and HIV-infection

  2008cites this paper
• Imatinib Quantification in rat plasma by high performance liquid chromatography with ultra violet detection - An application to Preclinical Pharmacokinetic study.

  2008cites this paper
• Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

  2008cites this paper
• TDM JOURNAL CLUB Improved Investigations in Drug Safety by More In-Depth Individual Pharmacokinetics Using High-Resolution Mass Spectrometry

  year unknowncites this paper
• A new HPLC-UV validated method for therapeutic drug kinase inhibitors in leukemic patients.

  year unknowncites this paper